Genentech, Inc. (Roche Group) / Tanox Inc.

Moderate-to-Severe Persistent Allergic Asthma

Disease Overview

Allergic asthma is a chronic inflammatory airway disease driven in large part by IgE-mediated mast-cell activation in response to environmental allergens. Moderate-to-severe persistent allergic asthma affects a meaningful subset of the ~25 million US asthma patients and accounts for a disproportionate share of exacerbations, emergency-department visits, and hospitalizations.

Competitive Landscape

When Genentech announced its $919M acquisition of Tanox in November 2006, Xolair (omalizumab) was the only approved anti-IgE biologic for moderate-to-severe allergic asthma — approved June 2003 — and was being co-promoted by Genentech and Novartis under a tripartite agreement with Tanox dating to 1996. The deal was unusual: this was Genentech's first acquisition in its 30-year history and was driven primarily by financial consolidation rather than pipeline expansion. By eliminating Tanox's royalty stream and acquiring Tanox's share of Novartis profit-share payments, Genentech captured the full economics of a fast-growing asset (US Xolair sales were +30% YoY at $107M in Q3 2006). At the time, severe asthma standard of care was inhaled corticosteroid + LABA combinations (Advair/GlaxoSmithKline, Symbicort/AstraZeneca), with oral corticosteroids reserved for refractory disease. The biologic class has since expanded dramatically — Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab) targeting IL-5; Dupixent (dupilumab) targeting IL-4Rα; and Tezspire (tezepelumab) targeting TSLP — but Xolair remains entrenched in IgE-driven phenotypes and was later approved for chronic urticaria (2014) and food allergies (2024).